Jiejie W. Liu
No. 28 Fuxing Road
Beijing, 100853, China
Beijing, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Manganese boosts natural killer cell function via cGAS-STING mediated UTX expression.
Journal: MedComm
Published: February 20, 2024
Predictive factors that influence the clinical efficacy of umbilical cord-derived mesenchymal stromal cells in the treatment of type 2 diabetes mellitus.
Journal: Cytotherapy
Published: September 02, 2023
Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes Assessed by Retrospective Continuous Glucose Monitoring.
Journal: Stem cells translational medicine
Published: January 15, 2023
Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial.
Journal: Stem cell research & therapy
Published: November 24, 2021
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Journal: Journal for immunotherapy of cancer
Published: March 09, 2021
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 12, 2021
Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation.
Journal: Frontiers in cell and developmental biology
Published: December 30, 2020
Reversion of early- and late-stage β-cell dedifferentiation by human umbilical cord-derived mesenchymal stem cells in type 2 diabetic mice.
Journal: Cytotherapy
Published: July 07, 2020
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2020
Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 09, 2020
Last Updated: 09/26/2026